Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
FENC

FENC - Fennec Pharmaceuticals Inc Stock Price, Fair Value and News

6.42USD+0.08 (+1.26%)Delayed as of 19 Jul 2024, 12:26 pm ET

Market Summary

FENC
USD6.42+0.08
Delayedas of 19 Jul 2024, 12:26 pm
1.26%

FENC Stock Price

View Fullscreen

FENC RSI Chart

FENC Valuation

Market Cap

173.2M

Price/Earnings (Trailing)

-20.02

Price/Sales (Trailing)

8.55

Price/Free Cashflow

6.3

FENC Price/Sales (Trailing)

FENC Profitability

Return on Equity

-287.06%

Return on Assets

-12.5%

Free Cashflow Yield

15.86%

FENC Fundamentals

FENC Revenue

Revenue (TTM)

21.3M

Rev. Growth (Yr)

566.71%

Rev. Growth (Qtr)

58.1%

FENC Earnings

Earnings (TTM)

-8.7M

Earnings Growth (Yr)

312.11%

Earnings Growth (Qtr)

175.68%

Breaking Down FENC Revenue

52 Week Range

6.358.97
(Low)(High)

Last 7 days

-3.1%

Last 30 days

-4.8%

Last 90 days

-32.2%

Trailing 12 Months

-26.5%

How does FENC drawdown profile look like?

FENC Financial Health

Current Ratio

6.93

Debt/Equity

8.29

Debt/Cashflow

1.1

FENC Investor Care

Shares Dilution (1Y)

3.42%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20233.2M9.2M15.2M21.3M
20220161.0K59.0K1.5M
202100230.0K174.0K
202000271.0K287.0K
2019355.0K392.0K361.0K315.0K
2018103.0K171.0K256.0K348.0K
201711.0K13.0K26.0K47.0K
201605.0K7.0K8.0K
20155.0K3.0K4.0K3.0K
201402.0K2.0K2.0K
201320.5K011.3K2.0K
201244.5K46.0K30.0K26.5K
201100043.0K

Tracking the Latest Insider Buys and Sells of Fennec Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 05, 2024
rallis chris a
acquired
4,999
2.79
1,792
-
Jul 05, 2024
rallis chris a
sold
-7,073
6.03
-1,173
-
Jul 02, 2024
raykov rosty
sold
-14,902
6.13
-2,431
chief executive officer
Jul 01, 2024
raykov rosty
acquired
-
-
2,431
chief executive officer
Jul 01, 2024
andrade robert
acquired
-
-
1,042
chief financial officer
Jun 03, 2024
raykov rosty
sold
-16,433
6.76
-2,431
chief executive officer
May 31, 2024
andrade robert
acquired
-
-
1,042
chief financial officer
May 31, 2024
raykov rosty
acquired
-
-
2,431
chief executive officer
May 01, 2024
raykov rosty
sold
-22,152
9.1123
-2,431
chief executive officer
Apr 30, 2024
raykov rosty
acquired
-
-
2,431
chief executive officer

1–10 of 50

Which funds bought or sold FENC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 10, 2024
CWM, LLC
added
362
-
-
-%
Jul 01, 2024
Legal & General Group Plc
unchanged
-
-204
18,895
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.9
-13,220
20,294
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
172,961
172,961
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-87.2
-29,861
4,337
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
112,999
112,999
-%
May 15, 2024
Solas Capital Management, LLC
reduced
-19.46
-3,121,120
12,345,800
7.94%
May 15, 2024
HARBERT FUND ADVISORS, INC.
unchanged
-
-46,687
5,191,580
3.57%
May 15, 2024
MORGAN STANLEY
reduced
-3.95
-41,620
823,880
-%
May 15, 2024
Avoro Capital Advisors LLC
sold off
-100
-13,464,000
-
-%

1–10 of 48

Are Funds Buying or Selling FENC?

Are funds buying FENC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own FENC
No. of Funds

Unveiling Fennec Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 27, 2024
dg capital management, llc
5.2%
1,416,456
SC 13G
Feb 14, 2024
solas capital management, llc
5.2%
1,378,513
SC 13G
Feb 14, 2023
sonic gp llc
9.2%
2,407,357
SC 13G/A
Feb 14, 2022
sonic fund ii, l.p.
9.3%
-
SC 13G/A
Feb 11, 2022
avoro capital advisors llc
4.6%
1,200,000
SC 13G/A
Feb 16, 2021
sonic fund ii, l.p.
9.4%
-
SC 13G
Feb 12, 2021
avoro capital advisors llc
6.5%
1,670,000
SC 13G/A
Feb 12, 2021
southpoint capital advisors lp
15.8%
4,077,214
SC 13G/A
May 04, 2020
essetifin spa
16.2%
3,993,694
SC 13D/A

Recent SEC filings of Fennec Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jul 08, 2024
4
Insider Trading
Jul 02, 2024
144
Notice of Insider Sale Intent
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
8-K
Current Report
Jun 27, 2024
SC 13G
Major Ownership Report
Jun 25, 2024
8-K
Current Report
Jun 03, 2024
144
Notice of Insider Sale Intent
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading

Peers (Alternatives to Fennec Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.5B
6.8B
-8.98% -3.09%
-7.79
6.94
-64.45% -224.75%
29.9B
2.0B
53.85% 15.29%
-90.16
14.95
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.8B
2.5B
-0.97% -4.31%
77.02
6.4
13.74% 186.89%
14.7B
3.8B
6.43% 3.96%
19.69
3.9
8.58% 129.81%
MID-CAP
4.9B
107.9M
-6.08% -24.75%
-8.88
48.09
54.84% -28.31%
4.6B
524.1M
-5.24% -6.22%
-11.04
8.79
394.93% 39.61%
3.9B
251.0M
7.93% 10.52%
-13.16
15.54
73.58% -86.73%
3.4B
240.7M
17.18% -20.08%
-7.26
12.77
-1.03% -213.92%
3.0B
813.8M
21.05% -43.59%
-1.7K
3.65
56.43% 98.83%
2.1B
996.6M
8.34% 84.22%
-5.26
2.1
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
11.69% 23.21%
30.33
4.8
60.38% -34.49%
565.8M
881.7K
20.84% 614.44%
-16.76
481.06
-77.61% 33.36%
269.0M
4.2M
21.26% 49.14%
-2.15
64.66
-66.30% 48.24%
18.2M
2.1M
-7.46% -80.82%
-0.79
7.61
-13.45% 69.54%

Fennec Pharmaceuticals Inc News

Latest updates
Yahoo Finance2 months ago

Fennec Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22021Q42021Q32020Q42020Q32019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q4
Revenue154.9%25,3779,9546,2963,9871,6771,49324.009.0013.0013.0012622.0069.0070.0011066.0011510173.0059.0023.00
Gross Profit-100.0%-9,0506,1843,1771,582----------------
Operating Expenses-37.7%11,63418,6647,201-7,8436,94712,5937,899-5,009----11,448--------
  S&GA Expenses34.7%5,2093,8683,3842,3402,531-10,2557,0533,8783,6842,9312,2934,4912,4811,0682,8441,0091,3821,0501,867--
  R&D Expenses-90.6%3.0032.0012.008.004.001178461,1315231,2421,2231,3681,1727951,9691,6711,7231,798798--
Interest Expenses71.3%197115102-10915324.00--------------
Net Income175.7%12,837-16,962917-5,444-6,052-6,857-8,089-5,072-4,427-4,185-3,238-6,200-3,610-1,809-4,730-2,626-2,984-2,749-2,587--
Net Income Margin68.6%-0.41*-1.30*-1.14*-2.87*-8.14*-15.41*-360.75*-107.95*-99.69*-70.25*-----------
Free Cashflow903.4%39,047-4,860-2,760-3,946-5,577-6,802-5,010-3,390-3,245-2,958-----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets157.6%69.0027.0020.0019.0022.0027.0030.0016.0019.0022.0026.0028.0028.0031.0034.0039.0010.0014.0016.0018.0021.00
  Current Assets153.8%68.0027.0020.0019.0022.0027.0030.0016.0019.0022.00-28.0028.0031.0034.0039.0010.0014.0016.0018.0020.00
    Cash Equivalents285.7%51.0013.0012.0015.0018.0024.0030.0015.0018.0021.0024.0027.0027.0030.0033.0039.0010.0014.0015.0014.0020.00
Liabilities72.0%66.0038.0030.0029.0029.0030.0028.007.007.007.007.006.004.002.002.002.002.002.00---
  Current Liabilities30.2%10.008.004.004.004.005.003.003.002.002.002.001.003.002.003.003.002.002.001.001.001.00
  Long Term Debt-------25.004.005.005.00-----------
    LT Debt, Current--------1.001.00------------
    LT Debt, Non Current-------25.004.005.005.00-----------
Shareholder's Equity125.9%3.00-11.6210.00--7.34-2.573.009.0013.0016.0019.0022.0025.0029.0031.0036.008.0012.0015.0016.0019.00
  Retained Earnings5.9%-206-219216-214-209-203-196-188-183-179-175-170-166-162-158-152-147-144-140-138-133
  Additional Paid-In Capital1.9%63.0062.0061.0060.0058.0057.0057.0055.0054.0053.0052.0051.0050.0049.0049.0049.0049.0048.0048.0047.0045.00
Shares Outstanding0.3%27.0027.0027.0027.0027.0026.0026.0026.0026.0026.0026.0026.0026.00--------
Float----138---98.00---98.00---116---46.00-
Cashflow (Last 12 Months)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations903.4%39,047-4,860-2,760-3,946-5,577-6,802-5,010-3,390-2,856-3,245-2,958-4,426-3,593-3,284-5,446-3,116-3,749-1,590-2,235-2,756-2,479
  Share Based Compensation39.0%1,1918578652,5431,0898271,8531,0083999199171,3265876401,2385223914613141,669221
Cashflow From Financing-119.8%-1,1325,73020151419382419,84746.0015.0010.00-4,968-462-11731,944-----71.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

FENC Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations  
PEDMARK product sales, net$ 7,419$ 1,677
Licensing revenue17,958 
Total revenue25,3771,677
Operating expenses:  
Cost of product sales55095
Research and development34
Selling and marketing5,2092,531
General and administrative5,8724,317
Total operating expenses11,6346,947
Net income/(loss) from operations13,743(5,270)
Other (expense)/income  
Unrealized foreign exchange (loss)/gain(38)9
Amortization expense(20)(72)
Unrealized loss on securities(11)(30)
Interest income197109
Interest expense(1,034)(798)
Total other expense(906)(782)
Net income/(loss) from operations$ 12,837$ (6,052)
Basic net income/(loss) per common share$ 0.41$ (0.23)
Diluted net income/(loss) per common share$ 0.41$ (0.23)
Weighted-average number of common shares outstanding basic27,04526,559
Weighted-average number of common shares outstanding diluted31,09126,559

FENC Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 51,184$ 13,269
Accounts receivable, net10,2748,814
Prepaid expenses4,4882,575
Inventory2,0642,156
Other current assets16144
Total current assets68,17126,858
Non-current assets  
Other non-current assets, net of amortization1,0226
Total non-current assets1,0226
Total assets69,19326,864
Current liabilities:  
Accounts payable5,2043,778
Accrued liabilities4,3633,754
Operating lease liability - current1721
Contract liability - current252 
Total current liabilities9,8367,553
Long term liabilities  
Term loan30,00030,000
PIK interest1,6171,219
Debt discount(268)(288)
Contract liability - long-term24,9942
Total long term liabilities56,34330,933
Total liabilities66,17938,486
Commitments and Contingencies (Note 6)
Stockholders' deficit:  
Common stock, no par value; unlimited shares authorized; 27,105 shares issued and outstanding (2023 27,027)144,934144,307
Additional paid-in capital63,24562,073
Accumulated deficit(206,408)(219,245)
Accumulated other comprehensive income1,2431,243
Total stockholders' deficit3,014(11,622)
Total liabilities and stockholders' deficit$ 69,193$ 26,864
FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
 CEO
 WEBSITEfennecpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES36

Fennec Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Fennec Pharmaceuticals Inc? What does FENC stand for in stocks?

FENC is the stock ticker symbol of Fennec Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fennec Pharmaceuticals Inc (FENC)?

As of Thu Jul 18 2024, market cap of Fennec Pharmaceuticals Inc is 173.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers.

What is the fair value of FENC stock?

You can check FENC's fair value in chart for subscribers. The fair value of Fennec Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Fennec Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FENC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Fennec Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether FENC is over valued or under valued. Whether Fennec Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fennec Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FENC.

What is Fennec Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, FENC's PE ratio (Price to Earnings) is -20.02 and Price to Sales (PS) ratio is 8.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FENC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fennec Pharmaceuticals Inc's stock?

In the past 10 years, Fennec Pharmaceuticals Inc has provided 0.191 (multiply by 100 for percentage) rate of return.